Introduction
Nicotinic acid (niacin) is the oldest lipid modifying drug and induces a unique spectrum of changes in lipid and lipoprotein levels (Carlson, 2005) . Besides its ability to decrease triglyceride and LDL cholesterol levels, it has the strongest HDL cholesterol elevating activity among the currently available lipid modifying drugs. Since a low HDL cholesterol level is an independent risk factor for cardiovascular diseases, the HDL cholesterol elevating effect of nicotinic acid has recently led to a renewed interest in this drug (Carlson, 2006; Kontush and Chapman, 2006; Offermanns, 2006) , and there is good evidence indicating a beneficial effect of nicotinic acid alone or in combination with statins (Brown et al., 2001; Coronary Drug Project Research Group, 1975; Taylor et al., 2004) .
The major problem of oral nicotinic acid treatment is the occurrence of a strong flushing phenomenon associated with cutaneous vasodilation which occurs in virtually all patients and severly influences patients' compliance. It has recently been shown that the nicotinic acid receptor GPR109A (HM74A in humans, PUMA-G in mice) mediates not only the acute metabolic effects of nicotinic acid but also the flushing response (Benyo et al., 2005; Tunaru et al., 2003) . However, the cells and molecular mechanisms mediating nicotinic acid-induced flushing are unclear.
The flushing response of nicotinic acid can be inhibited by pre-treatment with cyclooxygenase inhibitors (Andersson et al., 1977; Eklund et al., 1979; Kaijser et al., 1979; Svedmyr et al., 1977) , and the levels of several vasodilatory prostanoids like prostaglandin E 2 (PGE 2 ) and prostaglandin D 2 (PGD 2 ) and their metabolites are elevated after administration of nicotinic acid Morrow et al., 1989; Nozaki et al., 1987; Stern et al., 1991) . These observations have led to the hypothesis that prostanoids are involved in nicotinic acid-induced flushing.
Pharmacological and genetic evidence has recently been provided that PGD 2 acting
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The cells required for nicotinic acid-induced and prostanoid-mediated flushing, however, remain elusive. The ability of topically applied nicotinic acid to induce locally restricted hyperemia (Morrow et al., 1992; Wilkin et al., 1985) and the fact that the nicotinic acid receptor GPR109A is expressed in macrophages and other immune cells (Schaub et al., 2001) suggests that immune cells of the skin are involved in the flushing response. This is supported by data demonstrating that MHC class II-positive skin cells express GPR109A, and that the lack of nicotinic acid-induced flushing response in GPR109A-deficient mice can be restored by the transplantation of wild type bone marrow (Benyo et al., 2005) . We therefore systematically studied the potential involvement of various cell types in the cutaneous effects of nicotinic acid. This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and methods
Mice. CD11b-DTR and CD11c-DTR mice were puchased (Jackson Lab, Bar Harbor, Maine, USA), and Langerin-DTR transgenic mice have been described previously (Bennett et al., 2005) . GPR109A deficient mice were kindly provided by Klaus Pfeffer (Universität Düsseldorf, Germany). Mice were housed in temperature-controlled facilities on a 12 h light-dark cycle with ad libitum food and water access. All experimental procedures were performed in accordance with institutional guidelines of the University of Heidelberg, Germany.
Measurement of flush.
Cutaneous blood flow was determined as described (9).
Shortly, anaesthetized mice were placed on their left side on a controlled heating pad and blood flow in the ear was determined with an LD probe (No. 407, Perimed AB, Stockholm, Sweden). Original LDF recordings were averaged for one second intervals, and the baseline LDF was determined prior to injection of the tested compound. All data are presented as mean ± SEM, n indicates the number of experimental animals. Statistical analysis of differences between flushing responses before and after DT treatment was performed by Student's paired t-test, p<0.05 was considered significant. Nicotinic acid was prepared in 5% (2-hydroxypropyl)-β-cylodextrin (Sigma) and the pH of the solutions was adjusted to 6.9-7.1 with 1 M NaOH. Prostaglandin D 2 (Cayman Chemical Co.) was dissolved in DMSO and diluted 20 times with saline.
DT treatment.
After control experiments the CD11b-DTR, CD11c-DTR and Langerin-DTR transgenic animals were treated with 25, 4 and 16 ng/g diphtheria toxin (Sigma), respectively, as described (Bennett et al., 2005; Duffield et al., 2005; Jung et al., 2002 Isolation of epidermal sheets, immunohistochemistry. Mouse ears were dissected, split into ventral and dorsal sheets and incubated for 50 min in RPMI and 10 mM EDTA. The epidermis was removed from the dermis using fine forceps and was fixed on ice for 1 hour in 4 % PFA/PBS. After permeabilization with 0.2% Triton/PBS for 10 min at 25 ºC and 2 washes with PBS for 10 min, the epidermal sheets were incubated with 10 % goat serum for 30 min. Polyclonal rabbit anti-PGE synthase 1, polyclonal rabbit anti-PGE synthase 2 and monoclonal mouse PGD 2 synthase (all from Cayman, Ann Arbor, USA) were each mixed with PE-labeled anti MHC II -IA/IE (BD PharMingen) in 10% goat serum/PBS and incubated with epidermal sheets overnight at 4ºC on a rotator. Secondary FITC labeled anti-rabbit and anti-mouse antibodies were applied together with DAPI in 1.5% horse serum for 2 hours on a rotator. After washing epidermal sheets were mounted and analyzed by fluorescence microscopy. 
Results
As previously reported, nicotinic acid-induced cutaneous vasodilation can be observed and quantified in the mouse ear using laser-Doppler (LD) flowmetry (Benyo et al., 2005; Cheng et al., 2006) . Intraperitoneal injection of nicotinic acid results within a few minutes in a biphasic increase in the blood flow which lasts for about 40 minutes. Based on the fact that transplantation of wild type bone marrow into GPR109A-deficient mice can restore the ability of nicotinic acid to induce flushing (Benyo et al., 2005) , we tested the potential involvement of various cutaneous immune cells in the nicotinic acid-induced flushing response. Since nicotinic acid does not induce an increase in histamine levels (Morrow et al., 1989 ) and since mast cell-deficient mice still respond with flushing to nicotinic acid (Benyo et al., 2005) (Jung et al., 2002) or in which diphtheria toxin receptor (DTR) expression is restricted to macrophages by using the CD11b promoter element (Duffield et al., 2005) . Murine cells are insensitive to DT because their DTR homologue does not bind DT. In both, CD11b-DTR and CD11c-DTR mice we were able to show that the systemic administration of DT led to depletion of macrophages and dendritic cells, respectively (Fig. 1a,b and f,g ). When DT-treated CD11b-DTR and CD11c-DTR mice were injected with nicotinic acid, a normal biphasic flushing response could be observed which was indistinguishable from the flushing response induced by nicotinic acid before DT treatment (Fig. 1c-e and h- (Fig. 2f-h ). Thus, epidermal Langerhans cells are specifically required for the nicotinic acid-induced cutaneous vasodilation and are positioned upstream of PGD 2 release.
j). This clearly indicates that neither
To test whether Langerhans cells functionally respond to nicotinic acid, we prepared epidermal sheets from ears of Langerin-DTR mice which express EGFP fused to DTR (Bennett et al., 2005) , and loaded epidermal cells with the Ca 2+ indicator Fura-2/AM. At the same time, Langerhans cells were visualized by fluorescence microscopy (Fig. 3a) . Exposure of Fura-2-loaded epidermal sheets to 100 µM nicotinic acid resulted in a transient increase in [Ca 2+ ] i of Langerhans cells Fig. 3b and c) . Fura-2 loaded Langerhans cells in epidermal sheets from GPR109A-deficient mice, which were identified by staining with and anti-MHCII antibody, did not respond with any increase in [Ca 2+ ] i to the application of nicotinic acid while still responding to the Ca 2+ ionophore ionomycin (Fig. 3d ).
Since PGD 2 and PGE 2 have been shown to be principal mediators of the nicotinic acid-induced flushing response, we tested whether epidermal Langerhans cells express prostaglandin D 2 and prostaglandin E 2 synthases. Staining of epidermal sheets from mouse ears with specific antibodies directed against murine PGD 2 synthase as well as type 1 and type 2 PGE 2 synthases (mPGES-1 and mPGES-2)
together with an antibody against mouse MHCII showed the presence of both PGD 2 synthase and type 2 PGE synthase whereas we were unable to detect type 1 PGE 2 synthase (mPGES-1) (Fig. 4) . The mPGES-2 enzyme appeared to be exclusively expressed in epidermal Langerhans cells, whereas prostaglandin D 2 synthase was also detected in other cells of the epidermis (Fig. 4) .
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Discussion
The nicotinic acid-induced flushing response is a phenomenon which was first described shortly after the discovery of nicotinic acid as a vitamin (Goldsmith and Cordill, 1943; Spies et al., 1938) . Previous studies have shown that PGD 2 and PGE 2 are critically involved in the nicotinic acid-induced flushing response (Benyo et al., 2005; Cheng et al., 2006) . In order to test whether Langerhans cells are principally able to synthesize both prostanoids we tested them for the expression of PGD 2 and PGE 2 synthases. We found both PGD 2 synthase as well as the constitutive type 2 PGE 2 synthase (mPGES-2) to be expressed in epidermal Langerhans cells. The inducible type 1 PGE synthase form (mPGES-1) (Kudo and Murakami, 2005) could, however, not be detected. This is consistent with earlier findings which showed that Langerhans cells are a major source of prostanoids in the epidermis, and that their main prostanoid product is PGD 2 while they are also able to synthesize PGE 2 (Rosenbach et al., 1990; Ruzicka and Aubock, 1987) . The nicotinic acid-induced flushing response is subject to a tolerance phenomenon which can be observed within days after repeated administration of nicotinic acid (Olsson, 1994) . Tolerance is unlikely to develop on the basis of receptor desensitization as the metabolic effects are stable even after long-term administration of nicotinic acid (Olsson, 1994) . It is more likely that the downstream mechanisms specific for the nicotinic acid-induced flushing response are involved. We could rule out the possibility that tolerance to nicotinic acid-induced flushing is due to any translocation of Langerhans cells, as repeated administration of nicotinic acid did not change the number of Langerhans cells per epidermal area although the vasodilatory effect had seized (data not shown). It is therefore more likely that the nicotinic acidinduced prostanoid formation in Langerhans cells undergoes tachyphylaxis. This would be consistent with the observation that the development of tolerance to nicotinic acid-induced flushing is accompanied by a reduced formation of prostanoids (Stern et al., 1991) . It has been described in the past that patients with atopic
This article has not been copyedited and formatted. The final version may differ from this version. dermatitis show a severely reduced flushing response to topical application of nicotinic acid esters (English et al., 1987; Uehara and Ofuji, 1977) . Thus, activation of Langerhans cells under certain pathological conditions like atopic dermatitis (Leung et al., 2004) 
